EMR1 Double Nickase Plasmid (h): sc-400698-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EMR1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- EMR1 Double Nickase Plasmid (h) and EMR1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ADGRE1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: F4/80 Antibody (C-7): sc-377009
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EMR1 Double Nickase Plasmid (h) | sc-400698-NIC | 20 µg | $410.00 | |||
EMR1 Double Nickase Plasmid (h2) | sc-400698-NIC-2 | 20 µg | $410.00 |
ADGRE1 encodes EMR1, an adhesion G protein–coupled receptor predominantly expressed on myeloid lineage cells, where it supports cell–cell interactions and immune surveillance within tissue microenvironments. As a member of the EGF-TM7 family, EMR1 contributes to leukocyte adhesion and signaling processes linked to cytoskeletal remodeling and regulated cell migration. EMR1 expression is widely used to annotate macrophage- and eosinophil-associated states, making it relevant to studies of inflammatory regulation and immune cell differentiation. Dysregulated myeloid activation and tissue infiltration patterns that track with EMR1-positive populations are frequently examined in chronic inflammatory settings and tumor-associated immune landscapes.
EMR1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ADGRE1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ADGRE1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ADGRE1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ADGRE1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.